[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"klatskin-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:klatskin-tumor":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,70,99,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100438734","liver-transplantation-for-non-resectable-perihilar-cholangiocarcinoma-100438734",false,"NCT04993131","Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma","Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma: a Prospective Exploratory Trial","TESLA II","Inclusion criteria\n\n* Radiologically strong suspicion of pCCA\n* Tumor can involve intrahepatic portal vein without thrombosis of extrahepatic portal vein\n* Tumor can involve hepatic artery distal to gastroduodenal artery or involve replaced hepatic artery\n* First time pCCA\n* Disease deemed not eligible for liver resection based on tumor location or underlying liver dysfunction\n* No extrahepatic disease, or lymph node involvement detected on imaging\n* No signs of extrahepatic metastatic disease according to PET-CT scan\n* No signs of extrahepatic metastatic disease according to CT or MR (chest\u002Fabdomen\u002Fpelvis) scan within 4 weeks prior to the faculty meeting at the transplant unit\n* At least 18 years of age\n* Good performance status, Eastern Cooperative Oncology Group (ECOG) score: 0 or 1\n* Satisfactory blood tests Hb \\>10g\u002Fdl, neutrophiles \\>1.0 (after any G-CSF), TRC \\>50, Bilirubin\\\u003C3 x upper normal level, ASAT, ALAT\\\u003C5 x upper normal level, Creatinine \\\u003C1.5 x upper normal level. Albumin above lower normal level, Normal IgG4 levels\n* Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to GCP, and national\u002Flocal regulations\n* Received chemotherapy for at least 6 months with at least 10% response according ti RECIST criteria and with no progression of disease at time of Lt\n* At least 10 months from diagnosis\n* Patient must be accepted for transplantation before progressive disease\n* Twelve months or more time span from the diagnosis of pCCA and date of being listed for liver transplantation\n\nExclusion criteria\n\n* Tumor involving common hepatic artery, celiac trunck or superior mesenteric artery the tumor\n* Tumor involving main portal vein\n* Tumor involving inferior vena cava\n* Perforation of the visceral peritoneum\n* Weight loss \\>15% the last 6 months\n* Patient BMI \\> 30\n* Other malignancies, except curatively treated more than 5 years ago without relapse\n* Known history of human immunodeficiency virus (HIV) infection\n* Prior history of solid organ or bone marrow transplantation\n* Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results\n* Known hypersensitivity to rapamycin\n* Prior extrahepatic metastatic disease\n* Women who are pregnant or breast feeding\n* Any reason why, in the opinion of the investigator, the patient should not participate","ALL","18 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"NA","The study will investigate whether liver transplantation provides increased survival, low side effects and good quality of life in patients with bile duct cancer where the tumor cannot be removed by normal surgery. Analyzes of blood and tissue samples from the tumor will be investigated to see if the analyzes can indicate who may have recurrence of the disease after liver transplantation. Furthermore, the effect of chemotherapy on normal liver and tumor tissues in the liver that are removed during transplantation will be investigated.",[27,28,29],"Perihilar Cholangiocarcinoma","Klatskin Tumor","Bile Duct Cancer","RECRUITING","2025-07-28",{"date":33,"type":34},"2025-07-31","ACTUAL",{"date":36,"type":34},"2021-09-01",{"date":38,"type":21},"2045-05-31",{"name":40,"class":41},"Oslo University Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100554026","stereotactic-body-radiation-therapy-after-chemotherapy-for-unresectable-perihilar-cholangiocarcinoma-100554026","NCT06493734","Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar Cholangiocarcinoma","Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: A Multicenter Phase II Trial (The STRONG 2 Trial)","STRONG II","Inclusion criteria translational part of the study:\n\nIn order to be eligible to participate in the translational part of the study, a subject must be discussed in a liver tumor board, should be eligible for gemcitabine-based chemotherapy (and immunotherapy, if applicable), and should meet all of the following criteria pre-chemotherapy:\n\n* Perihilar cholangiocarcinoma (pCCA) according to the criteria of the Mayo Clinic, Rochester: a positive or strongly suspicious intraluminal brush cytology or biopsy, or a radiographic malignant appearing stricture plus either: CA 19-9\\>100 U\u002Fml in the absence of acute bacterial cholangitis, or polysomy on fluorescence in situ hybridization (FISH), or a well-defined mass on cross sectional imaging\n* One tumor mass\n* Unresectable tumor or patient deemed unfit for surgery\n* T1-T4 (AJCC staging 8th edition), N0-N2-M0 (AJCC staging 8th edition), radiologically or pathologically suspect. N1 is defined as one to three affected lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. N2 is defined as four or more affected lymph nodes from the sites described for N1. Endoscopic ultrasound (EUS) is leading in identifying pathological lymph nodes compared to CT.\n* In case of (underlying) liver cirrhosis: Child-Pugh A\n* Age ≥ 18 years\n* ECOG performance status 0-1\n* Written informed consent for the translational part of the study\n\nInclusion criteria SBRT part of the study:\n\nIn addition to the criteria mentioned above, patients should meet the following criteria to be eligible for the treatment with SBRT:\n\n* Measurable disease to be selected as a target on a computed tomography (CT) or magnetic resonance imaging (MRI) scan, according to RECIST 1.1 criteria\n* Finished gemcitabine-based chemotherapy treatment, preferably 8 cycles. If less cycles are given, patients are still eligible for this study\n* Bilirubin ≤3.0 times normal value, aspartate aminotransferase (AST)\u002Falanine transaminase (ALT) ≤5 times ULN\n* Platelets ≥ 50x10E9\u002F l, Leukocytes \\> 1.5x10E9\u002Fl, Hemoglobin (Hb) \\> 6 mmol\u002Fl\n* Willing and able to comply to the follow-up schedule\n* Able to start SBRT within 12 weeks after completion of chemotherapy and immuno-therapy (if applicable)\n* Written informed consent for the SBRT part of the study\n\nExclusion criteria translational part of the study:\n\n* Prior surgery or transplantation of the liver\n* Tumor extension in stomach, colon, duodenum, pancreas or abdominal wall\n* Ascites\n* Prior radiotherapy to the liver\n* Current pregnancy\n* Affected lymph nodes outside the regions described in the inclusion criteria\n\nExclusion criteria SBRT part of the study:\n\nProgression (local or distant) during or after chemotherapy",{"count":52,"type":21},30,[24],"The objective of this study is to evaluate the efficacy of stereotactic body radiation therapy (SBRT) as additional treatment after standard chemotherapy regarding tumor local control, toxicity, progression-free survival (PFS), overall survival and quality of life. In addition, the objective is to explore the value of immunodynamics in peripheral blood for predicting PFS in patients undergoing chemotherapy.",[28],[57,58,59],"Klatskin tumor","Perihilar cholangiocarcinoma","Stereotactic body radiation therapy","2025-07-10",{"date":62,"type":34},"2025-07-15",{"date":64,"type":34},"2024-07-01",{"date":66,"type":21},"2028-03-01",{"name":68,"class":41},"Erasmus Medical Center",8,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":42},"100590208","raman-spectroscopy-in-the-diagnosis-of-extrahepatic-cholangiocarcinoma---a-pilot-study-100590208","NCT06964425","Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study","Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma","Inclusion Criteria:\n\n* person older than 18 years, who has known extrahepatic cholangiocarcinoma and is indicated for ERCP\n\nExclusion Criteria:\n\n* disagreement with the study",{"count":78,"type":21},20,[24],"Diagnosis of extrahepatic cholangiocarcinoma is challenging because the yield of imaging and tissue sampling is limited. Raman spectroscopy is an optical method based on the analysis of scattered monochromatic light. Raman spectroscopy is able to provide a molecular 'fingerprint' of the tissue to determine its type. The aim of this pilot study was to develop a methodology for in vivo Raman spectroscopy in bile ducts to improve the current diagnostic capabilities of extrahepatic cholangiocarcinoma.",[82,83,84,85,86,28,87,88,89],"Cholangiocarcinoma, Extrahepatic","Cholangiocarcinoma of the Extrahepatic Bile Duct","Cholangiocarcinoma, Perihilar","Diagnosis","Raman Spectroscopy","Endoscopy","Biliary Stricture","Malignant Biliary Stricture","2025-06-29",{"date":92,"type":34},"2025-07-02",{"date":94,"type":34},"2023-02-04",{"date":96,"type":21},"2025-07-30",{"name":98,"class":41},"University Hospital Olomouc",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":42},"100591904","liver-transplantation-for-unresectable-perihilar-cholangiocarcinoma-100591904","NCT06986486","Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma","Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy Followed by Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma: pCOLA","pCOLA","Inclusion Criteria:\n\n* Diagnosis of unresectable peripheral cholangiocarcinoma arising one centimeter or more above the superior pancreatic margin, with tumor diameter ≤ 3 cm, diagnosed by:\n* Transcatheter biopsy or brush cytology\n* CA-19.9 \\> 100 mg\u002Fml and\u002For a mass on cross-sectional imaging with a malignant appearing stricture on cholangiography\n* Biliary ploidy by FISH with a malignant appearing stricture on cholangiography\n* Age between 18 years and 70 years\n* Absence of intra- and extrahepatic metastases\n* Absence of lymph-nodal metastases at any site\n* Biliary stenting of all liver districts\n* No contraindications to liver transplantation\n* No concomitant malignancies or history of other malignancies in the previous 5 years\n* Written informed consent\n\nExclusion Criteria:\n\n* Intrahepatic cholangiocarcinoma\n* Uncontrolled infection\n* Concomitant malignancies or history of other malignancies in the previous 5 years","70 Years",{"count":69,"type":21},"OBSERVATIONAL","This is multicentric, single-arm, observational, investigator-drive study investigating the efficacy of liver transplantation after successful downstaging\u002Fdisease control of unresectable perihilar cholangiocarcinoma using chemotherapy +\u002F- immunotherapy and stereotactic body radiation therapy (SBRT).",[27,28],[113,114,115],"liver transplantation","stereotactic body radiation therapy","downstaging","2025-05-15",{"date":118,"type":34},"2025-05-23",{"date":120,"type":21},"2025-06-01",{"date":122,"type":21},"2030-01-01",{"name":124,"class":41},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":42},"100529597","endoscopic-radiofrequency-ablation-for-unresectable-cholangiocarcinoma-100529597","NCT06175845","Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma","Radiofrequency Ablation Via Catheter and Transpapillary Access in Patients With Cholangiocarcinoma","ACTICCA-2","Inclusion Criteria:\n\n1. Unresectable perihilar and\u002For ductal CCA with bile duct stenting and palliative systemic therapy as indicated by the local Multidisciplinary Team (MDT)\n2. Written informed consent\n3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n4. Age ≥18 years\n5. Eligibility for palliative systemic therapy based on clinical and laboratory parameters (except hyperbilirubinemia) as determined by the local MDT\n6. No prior radiofrequency ablation (RFA) for CCA\n7. No repeated bile duct stenting in the past 3 months (trial inclusion is possible upon first stent replacement or initial stent placement within past 3 months)\n8. No concomitant disease or malignancy interfering with the study procedure or efficacy outcome measures, particularly no severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, unstable angina pectoris, myocardial infarction within ≤3 months, significant arrhythmias) and no psychiatric disorders precluding understanding of information of trial related topics and giving informed consent",{"count":134,"type":21},130,[24],"The goal of this clinical trial is to learn about radiofrequency ablation in patients with unresectable bile duct cancer who receive systemic chemotherapy and bile duct stenting. The main questions it aims to answer are:\n\n* Does radiofrequency ablation of tumorous bile duct occlusion reduce risk of complications in these patients (eg stent dysfunction, delay of chemotherapy, infections etc)?\n* Is radiofrequency ablation safe in these patients? All participants will receive standard treatment with systemic chemotherapy and bile duct stenting. Researchers will compare two groups (one group will receive additional radiofrequency ablation, the other not).",[138,28,29,139],"Cholangiocarcinoma","Liver Cancer",[141,142,143,144,145,146,147,148],"Radiofrequency ablation","Intraductal","Biliary","Endoscopic retrograde cholangiography","Transpapillary","Stent dysfunction","Cholangitis","Obstruction","NOT_YET_RECRUITING","2023-12-08",{"date":152,"type":34},"2023-12-19",{"date":154,"type":21},"2024-02",{"date":156,"type":21},"2026-07",{"name":158,"class":41},"Universitätsklinikum Hamburg-Eppendorf"]